This study aimed to assess the impact of antithymocyte globulin (ATG) on patient outcome in a retrospective series of 91 patients (median age: 12 years) who underwent unrelated single-unit cord blood transplantation (allo-CBT) following a myeloablative conditioning regimen. Cord blood units were HLA-matched (6/6, n = 18; 21%), one-Ag mismatched (n = 30, 35%) or two-Ag mismatched (n = 38; 44%). In this series, the OS, nonrelapse mortality (NRM) and cumulative incidence of relapse were 47 ± 6%, 23 ± 4% and 48 ± 5%, respectively. Among 46 patients who received ATG as part of the conditioning regimen, the incidence of acute and chronic GVHD was lower than that in the group of 45 patients who did not receive ATG (20% vs 43%; P = 0.03). However, multivariate statistical analysis revealed that the ATG use was associated with decreased OS and EFS rates and a high incidence of NRM (hazard ratio (HR) = 1.99, 95% confidence interval (CI): 1.11-3.59, P = 0.02), (HR = 1.83, 95% CI: 1.08-3.10, P = 0.02) and (HR = 2.54, 95% CI: 1.03-6.26, P = 0.04), respectively. Therefore, our results do not support the use of ATG as part of a myeloablativeconditioning regimen before single-unit allo-CBT in younger patients with hematological malignancies.
INTRODUCTION
Allogeneic hematopoietic SCT (allo-SCT) is a curative therapeutic approach in a wide variety of otherwise incurable hematological disorders. 1 Unrelated umbilical cord blood transplantation (UCBT) has emerged as a valid alternative source of stem cells in patients lacking a suitable HLA-matched related or unrelated donor. [2] [3] [4] [5] [6] The feasibility of myeloablative conditioning in UCBT was demonstrated in 2003. 7 In comparison to conventional BM and peripheral blood cell grafts, UCB contains significantly fewer CD34 + cells and mature lymphocytes. 8 The latter could be responsible for an increased risk of late engraftment and graft failure and for delayed post-transplant immune reconstitution leading to a high incidence of early nonrelapse mortality (NRM). 9 One of the strategies developed to reduce the risk of graft rejection has been to provide for in vivo recipient T-cell depletion in blood and lymphoid tissues by using antithymocyte globulin (ATG), a set of polyclonal antibodies directed against a wide range of immune cell epitopes. 10, 11 However, ATG use in combination with a conditioning regimen before allo-SCT is still controversial, especially for patients receiving a myeloablative single-unit cord blood transplantation (allo-CBT). 12 The aim of this multicenter retrospective study was to assess the impact of ATG on the outcome of 91 consecutive patients who underwent a single-unit allo-CBT following a myeloablative conditioning regimen at three French transplant centers.
PATIENTS AND METHODS
This study was conducted according to the Declaration of Helsinki and included 91 consecutive patients who underwent a myeloablative single-unit allo-CBT in Lille (n = 38), Nantes (n = 31) and Bordeaux (n = 22) between January 2000 and December 2010. The following inclusion and exclusion criteria were used: only patients who underwent their first UCBT were selected. Participating centers were asked to verify the data recorded for each patient in the French Bone Marrow Transplantation Registry. Eurocord provided additional information. HLAmatching data were also cross-checked, and grafts were matched for at least four out of six HLA loci by standard cord criteria (that is, low resolution for HLA-A and HLA-B, and high resolution for HLA-DR). All patients received myeloablative conditioning and were divided into ATG (n = 46) and no-ATG (n = 45) groups. Except for one patient who discontinued ATG owing to intolerance, the median ATG dose administered to ATG group patients was 5 mg/kg of recipient body weight (range 3.8-7.5 mg), and the median number of treatment days was 2 (range 1-5 days). The drug was stopped at a median time of 5 days before transplantation (range 1-10 days). Only patients receiving the drug Thymoglobuline (Genzyme Corporation, Cambridge, MA, USA) were included in the study because this drug was the only ATG brand name licensed for use in allo-SCT in France.
As shown in Table 1 , the two groups were comparable in terms of patient and graft characteristics and transplantation modalities. The median age at transplantation was 12 years (range 0.7-56 years), and there were 54 (59%) males and 37 (41%) females. 
Statistical analyses
The patients' clinical endpoints of this study were analyzed as of 1 January 2013. OS was defined as the time interval from allo-UCBT to the patients' death, regardless of the cause of death. Relapse was defined as the recurrence of the underlying hematological malignancies with or without evidence of autologous BM reconstitution based upon available hematopoietic chimerism data. EFS was defined as patients' survival with no evidence of disease relapse. NRM was defined as patients' death without evidence of relapse of their hematological malignancies. Patient-, disease-and transplant-related variables of the two study groups were compared using χ 2 or Fisher's exact test for categorical variables and
Mann-Whitney test for continuous variables, respectively. Cumulative incidence functions were used to estimate relapse incidence and NRM in the presence of two competing risks: relapse of malignancy or death in remission. 13 To study acute and chronic GVHD, we considered death in remission as a competing event. Probabilities of EFS and OS were calculated using the Kaplan-Meier estimate. Univariate analyses were performed using the log-rank test for OS and LFS and Gray's test for cumulative incidence functions. Multivariate analyses were performed using the Cox proportional-hazard model.
14 Differences between the two groups with regard to distribution and all variables significantly associated with one of the outcomes studied were included in the statistical model. All statistical tests were two-sided with the type-I error rate fixed at 0.05. Statistical analyses were performed using SPSS 18 (SPSS Inc., Chicago, IL, USA) and R 2.13.2 (R Development Core Team, Vienna, Austria) software packages.
RESULTS

Engraftment and transplant-related toxicity
In this study, 11 patients did not show evidence of neutrophil engraftment following allo-UCBT; of these patients, 9 died soon after graft infusion, and 2 others developed autologous marrow cell reconstitution. The estimated median time interval to reach a neutrophil count of 0.5 G/L was 28 days after transplant (range 13-84 days). Three patients eventually rejected their grafts after sustained engraftment (at days 58, 60 and 84). The 100-day cumulative incidences of grade II-IV and grade III-IV acute GVHD (aGVHD) were 35% and 19%, respectively. Of the 62 evaluable patients who survived 4100 days, 19 (31%) developed chronic GVHD, including 6 cases (10%) with extensive grade. Table 2 summarizes the post-transplant complications observed in both patient groups. The cumulative incidence of grade II-IV acute GVHD was 38 ± 8% in the 'no-ATG' group versus 32 ± 7% in the ATG group (P = 0.43). The cumulative incidence of grade III-IV aGVHD was 22 ± 7% in the 'no-ATG' group and 16 ± 6% in the ATG group (P = 0.43). Patients from the 'no-ATG' group developed chronic GVHD more frequently than those from the ATG group (13 vs 6, P = 0.04).
Survival
With a median follow-up period of 33 months (range 12-96 months), the estimated 3-year OS, EFS, cumulative incidence of relapse and NRM rates were 47 ± 6%, 30 ± 5%, 48 ± 5% and 23 ± 4%, respectively (Figure 1) . In univariate statistical analysis (Table 3) , older transplant recipients (age 418 years) were found to have worse OS, EFS and NRM (P = 0.004, P = 0.03 and P = 0.01, respectively), whereas pretransplant positive CMV) serostatus was Table 1 . Initial characteristics of patients recipients and donors
Characteristics
Main characteristics of the patients and donors (N = 91) b Two of these patients also developed aGVHD, and 2 others veno-occlusive disease.
ATG in conditioning regimens for cord blood transplantation L Pascal et al correlated with worse OS and NRM (P = 0.002 and P = 0.007, respectively). Infusion of a low total nucleated cell dose (o 4.6 × 10 7 nucleated cells/kg) was associated with an increased NRM (P = 0.006). In addition, poor disease status at the time of transplant was associated with an increased risk of relapse (P = 0.03). A trend toward shorter EFS was noted in the ATG group (P = 0.07). Pretransplant positive CMV serostatus was found to be associated with a worse OS (hazard ratio (HR) = 1.89, 95% confidence interval (CI) (1.01-3.54); P = 0.05). No impact of ATG on aGVHD development was detected regardless of their grades.
In multivariate statistical analyses (Table 4) , ATG use was the only variable that adversely influenced OS, EFS and NRM (HR = 1.99, 95% CI (1.11-3.59); P = 0.02), (HR = 1.83, 95% CI (1.08-3.1); P = 0.02) and (HR = 2.54, 95% CI (1.03-6.26); P = 0.04), respectively.
Cause of death As shown in Table 2 , 12 (13%) patients died of post-transplant infectious causes, including 5 bacterial, 2 viral, 3 fungal and 2 mixed infections. Two of these infected patients also developed veno-occlusive disease. In the ATG group, infections were the main cause of death. Eight out of 46 patients from the ATG-group developed fatal infections as compared with 4/45 patients from the no-ATG group, but this difference was not statistically significant. At 1 year after transplant, NRM was 30% in the ATG group and 15% in the no-ATG group (P = 0.48; Table 3 ).
DISCUSSION
The most important finding of our study is that the addition of rabbit ATG to the myeloablative conditioning regimen before single-unit allo-CBT adversely influenced patients' outcomes, particularly their survival and NRM. To the best of our knowledge, this is the largest study of this kind on the role of ATG in the myeloablative conditioning regimens in the setting of single-unit allo-CBT. Previous studies have reported on ATG in the pretransplantation setting. 15, 16 However, none of these reports specifically addressed the impact of ATG on patient outcome.
In this study, only patients who received standard myeloablative conditioning were included. Because the incidence of delayed neutrophil recovery and graft failure is commonly reported to be higher in transplant patients infused with a single-unit of cord blood, 17 we deliberately chose to limit our study to this category of patients based on the hypothesis that administration of ATG before transplant could have a significant impact on patient outcome in this setting. Information about HLA matching between donor and recipient was verified in the databases of the French National Donor Registry and Eurocord. In addition, these results were meticulously cross-checked using different verification methods (for example, matching of several sources of data, onsite verification and computerized search for discrepancies or errors).
In agreement with other reports, [18] [19] [20] [21] [22] we observed that the myeloablative conditioning regimen lacking ATG resulted in a higher incidence of aGVHD development. One may ask why the beneficial effect of ATG in reducing aGVHD does not translate into benefits in patient survival. Indeed, measuring the outcome of allo-SCT therapy is challenging because the net outcome is affected by several complex variables. In the present study, patients from the ATG group were noted to experience fatal infections and relapse of their disease more frequently than those from the no-ATG group, although this difference was not statistically significant. As reported by other authors, delayed immune reconstitution following allo-CBT has been known to be associated with a high incidence of infections and relapse especially after myeloablative conditioning. [23] [24] [25] [26] [27] To further characterize the adverse influence of ATG in our patient cohort, we sought to analyze the role of the dosing of ATG, Abbreviations: ATG = antithymocyte globulin; CI = confidence interval; HR = hazard ratio; NRM = nonrelapse mortality. Significant values are indicated in bold.
ATG in conditioning regimens for cord blood transplantation L Pascal et al duration of perfusion and timing on patients' outcome. However, because the majority of patients received ATG at a total dose of 5 mg/kg with a median of 2 days of perfusion, comparisons with other ATG protocols lacked sufficient statistical power. In addition, based on our experience and various other reports, it is likely that the use of low to moderate doses (5-7 mg/kg) of ATG before allo-SCT can decrease the risk of GVHD without compromising other post-transplant outcomes. 28, 29 An alternative approach to ATG administration could be the use of a fludarabine-based regimen because this chemotherapeutic agent is known to have a powerful immunosuppressive effect resulting in long-lasting engraftment; 7 however, its use in HLAmismatched transplantation needs to be established. In fact, it is because of ATG's beneficial effects in cases of HLA disparities that ATG has been recommended. 11, 22, 28 Although we acknowledge the limitations of our retrospective study based on a relatively small number of mostly young patients, our results suggest that the use of ATG during myeloablative conditioning of patients receiving single-unit allo-CBT should be handled cautiously outside the clinical trial setting. From our study, no conclusions can be drawn with certainty concerning patients who received nonmyeloablative conditioning and those transplanted with double-unit cord blood or with in vitro expanded cord blood. Our study emphasizes the need to delineate the indications for the use of ATG and to perform prospective protocols that investigate the dose, scheduling and timing of ATG in allo-CBT.
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